Clinical Trials Sponsored by Priyanka Sharma

Total 12621 results

LEO Pharma

Completed

LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients

Secondary Hyperparathyroidism

Germany, Poland
LEO Pharma

Withdrawn

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese

Healthy

United Kingdom
LEO Pharma

Withdrawn

Investigation of Flare and Remission in Subjects With Atopic Dermatitis

Atopic Dermatitis

Netherlands
LEO Pharma

Terminated

Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema

Infected Atopic Dermatitis/Eczema

China
UCB Pharma

Completed

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

Epilepsy

United States, France, Hungary, Mexico, Poland
LEO Pharma

Completed

LEO 124249 Ointment in the Treatment of Alopecia Areata

Alopecia Areata

United States
LEO Pharma

Completed

A Vasoconstriction Study With LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis

Deep Vein Thrombosis

Bulgaria, Croatia, Czechia, France, Germany, Poland, Romania, Serbia, Spain
MaaT Pharma

Terminated

Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY (HAPY3)

Intensive Care Units | Fecal Microbiota Transplantation

France
Iltoo Pharma

Completed

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) (LUPIL-2)

Systemic Lupus Erythematosus

France, Spain, Mexico, Austria, Germany, Bulgaria, Italy, Mauritius, Portugal, Romania
LEO Pharma

Completed

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

Acne Vulgaris

United States
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
LEO Pharma

Completed

The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice (PrAKtice)

Actinic Keratosis

Greece
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis

Inverse Psoriasis

Germany
LEO Pharma

Completed

An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

Psoriasis Vulgaris

United States, Canada, United Kingdom, Germany, Romania, France, Poland
UCB Pharma

Completed

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

Epilepsy

United States, Mexico, India, Brazil
LEO Pharma

Completed

Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation

Plaque Psoriasis | Psoriasis Vulgaris

Germany
UCB Pharma

Completed

A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen

Rhinitis | Allergic | Seasonal

Canada
LEO Pharma

Completed

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

Secondarily Infected Traumatic Lesions | Impetigo

United States, South Africa
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 90100 Foam

Healthy

Japan
UCB Pharma

Terminated

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease (COSPAR1)

Crohn's Disease

United States, Germany, Canada
UCB Pharma

Completed

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

Crohn Disease

United States, Australia, Italy, Ukraine, Germany, Belgium, Israel, Romania, Canada, New Zealand, Brazil, Estonia, Russian Federation, Chile, Austria, Poland, Hungary, Latvia, Czechia, Finland
UCB Pharma

Completed

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease (Welcome2)

Crohn's Disease

United States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Austria, Sweden
UCB Pharma

Completed

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

Crohn's Disease

United States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Denmark, Austria, Norway, Sweden
Dermis Pharma

Completed

DERMALIX Efficacy on Diabetic Foot Ulcers (DERMAN)

Diabetic Foot | Diabetic Foot Ulcer

Turkey
UCB Pharma

Completed

Dosing Flexibility Study in Patients With Rheumatoid Arthritis (DoseFlex)

Rheumatoid Arthritis

United States, France, Canada
UCB Pharma

Completed

Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, United Kingdom, Belgium, Germany, Austria, Ireland, Czechia
UCB Pharma

Completed

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (REALISTIC)

Rheumatoid Arthritis

United States, France, Italy, Germany, Spain, Canada, Netherlands
UCB Pharma

Completed

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA) (Dose Flex II)

Rheumatoid Arthritis

United States, Canada
UCB Pharma

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)

Rheumatoid Arthritis

Germany, United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, France, Hungary, Ireland, Italy, Mexico, Monaco, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
UCB Pharma

Completed

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

Fibromyalgia Syndrome

United States
UCB Pharma

Completed

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis (SP906)

Migraine

United States
UCB Pharma

Completed

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Epilepsy

United States, Czechia, Germany, Poland
LEO Pharma

Terminated

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Alopecia Areata

Denmark
Patara Pharma

Completed

Treatment of Uremic Pruritus With PA101B

Uremic Pruritus

United States
Kukje Pharma

Completed

KJ-TFC-004 Drug-drug Interaction Study

Ocular Hypertension | Glaucoma | Eye Diseases

Korea, Republic of
Zealand Pharma

Completed

Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

Focus of Study is STEMI

Denmark
LEO Pharma

Completed

An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life

Psoriasis Vulgaris

United States
UCB Pharma

Completed

Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

Epilepsy

France, Poland, United Kingdom, Germany, Spain, Finland, Australia, Russian Federation, Hungary, Lithuania, Sweden, Czechia, Croatia
LEO Pharma

Completed

Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response

Skin Inflammation

Australia
Vifor Pharma

Completed

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Chronic Heart Failure | Iron Deficiency

Netherlands
LEO Pharma

Completed

Vasoconstriction Trial With LEO 90100 Aerosol Foam

Psoriasis Vulgaris

France
LEO Pharma

Completed

Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

Anogenital Warts

Denmark
LEO Pharma

Completed

LEO 32731 - A Phase I Study in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
Zealand Pharma

Completed

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Diabetes Mellitus Type 1

Germany
Innate Pharma

Terminated

Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity

Squamous Cell Carcinoma of the Oral Cavity

Germany, Spain
Patara Pharma

Completed

Treatment of Indolent Systemic Mastocytosis With PA101

Systemic Mastocytosis | Mastocytosis | Indolent Systemic Mastocytosis

France, Germany, Spain, Italy, Netherlands

3

Subscribe